Highest-materiality recent filing
FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's
VY1706 targets intra- and extracellular tau; IND cleared by FDA on June 1, 2026.
Voyager Q1 net loss $27.9M, cash $172M into 2028; VY1706 tau gene therapy on track for H2 dosing
Net loss $27.9M (Q1 2026) vs $31.0M (Q1 2025); revenue $2.6M down from $6.5M due to lower collaboration revenue.
Voyager Q4 2025 net loss $27.4M, cash $201.7M; key pipeline milestones H2 2026
Q4 2025 net loss $27.4M vs $34.5M in Q4 2024; full year net loss $119.7M vs $65.0M.
Chief Medical Officer Toby Ferguson resigns; CEO Sandrock takes over clinical leadership
Toby Ferguson, M.D., Ph.D., resigned as CMO effective Feb 20, 2026, to pursue a new opportunity.
Biogen's BIIB080 Phase II data expected mid-2026; Voyager's VY1706 gene therapy first-in-human in H2 2026.
Voyager Q3 net loss widens to $27.9M; cash runway into 2028; NeuroShuttle platform launched
Net loss of $27.9M (vs $9.0M in Q3 2024); collaboration revenue fell to $13.4M from $24.6M.
Voyager Q2 net loss widens to $33.4M; cash runway extended into 2028
Net loss $33.4M in Q2 2025 vs $10.1M in Q2 2024; collaboration revenue fell to $5.2M from $29.6M.
Voyager Q1 2025 net loss $31.0M, revenue down 67% YoY; cash $295M into mid-2027
Net loss $31.0M vs $11.3M YoY; collaboration revenue $6.5M vs $19.5M YoY (−67%).
Voyager Therapeutics Q4 2024 net loss $34.5M; tau gene therapy VY1706 IND filing planned for 2026
Net loss $34.5M in Q4 2024 vs net income $56.4M in Q4 2023; full year net loss $65.0M vs income $132.3M.
Voyager Q3 net loss narrows to $9.0M; new Novartis capsid license; VY7523 SAD data H1 2025
Q3 collaboration revenue $24.6M (up from $4.6M YoY); net loss $9.0M vs $25.9M.
Voyager grants Novartis license to capsid for gene therapy; $15M upfront, up to $305M milestones
Novartis receives exclusive license to a capsid from Voyager's TRACER platform for a single gene target.
Voyager Q2 net loss narrows to $10.1M; cash $371M; anti-tau trial underway, data H1 2025
Q2 collaboration revenue $29.6M (vs $4.9M YoY); net loss $10.1M vs $22.2M loss a year earlier.
First participants dosed in Phase 1a SAD trial of VY-TAU01, an anti-tau antibody for Alzheimer's disease.
Voyager Q1 net loss $11.3M; IND cleared for VY-TAU01; cash $400M to 2027
Net loss of $11.3M vs net income of $124.0M in Q1 2023; collaboration revenue $19.5M down from $150.5M.
CFO Peter Pfreundschuh resigns effective April 12, 2024; remains as Senior Financial Advisor until May 5, 2024.
Voyager Therapeutics reports Q4 net income $56.4M, pro-forma cash $431M, pipeline milestones
Q4 collaboration revenue $90.1M (vs -$1.6M YoY), net income $56.4M (vs loss $23.6M).
On June 11, 2024, Voyager Therapeutics, Inc. (the “Company”) and Nathan Jorgensen entered into an employment agreement (the “Jorgensen Agreement”), pursuant to which Dr. Jorgensen agreed to serve as the Chief Financial Officer of the Company, with his employment to commence no later than July 8, 2024
Max materiality 0.75 · Median 0.60 · Most common event earnings